Edition:
United Kingdom

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

7.95USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$7.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
21,571
52-wk High
$11.73
52-wk Low
$5.60

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $123.10
Shares Outstanding(Mil.): 16.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.24 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Cidara Therapeutics announces pricing of $20 mln private placement

* Cidara Therapeutics announces pricing of $20 million private placement of common stock

19 Oct 2017

BRIEF-Cidara Q2 net loss per share $0.99​

* Cidara provides corporate update and reports second quarter 2017 financial results

09 Aug 2017

BRIEF-Cidara Therapeutics updates on results from studies investigating antifungal CD101

* Cidara therapeutics inc - ‍announces publication of results from in vivo study investigating novel antifungal CD101 in intra-abdominal candidiasis (IAC)​

01 Aug 2017

BRIEF-Broadfin Capital reports 5.28 percent passive stake in Cidara Therapeutics as of July 7

* Broadfin Capital LLC reports a 5.28 percent passive stake in Cidara Therapeutics Inc as of July 7, 2017 - SEC filing Source text for Eikon: Further company coverage:

13 Jul 2017

BRIEF-Prosight Management LP reports 5.2 pct passive stake in Cidara Therapeutics - SEC filing

* Prosight Management LP reports a 5.2 percent passive stake in Cidara Therapeutics Inc as of June 7, 2017 - SEC filing Source text - (http://bit.ly/2rEN8RH) Further company coverage:

16 Jun 2017

Earnings vs. Estimates